Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Kronos Bio Inc (NQ: KRON )

0.9500 -0.0100 (-1.04%)
Streaming Delayed Price Updated: 1:00 PM EST, Nov 29, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Kronos Bio Inc

< Previous 1 2 3 4 Next >
Kronos Bio Announces Changes to Board of Directors
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Reports Recent Business Progress and Fourth-Quarter and Full-Year 2022 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in 43rd Annual Cowen Health Care Conference
From Kronos Bio, Inc.
Via GlobeNewswire
5 Most Expensive Health Care Stocks You Should Worry About
The most overbought stocks in the health care sector presents an opportunity to go short on these overvalued companies. 
Via Benzinga
Expert Ratings for Kronos Bio
Via Benzinga
Kronos Bio Starts Dosing In Early-Stage Leukemia Study With Next-Gen SYK Inhibitor
Via Benzinga
The Week In Charts: Millon-Dollar Trade Missed?
Recent big winners and how we picked them, nuances of trend trading, and answering your questions. 
Via Talk Markets
Recap: Kronos Bio Q4 Earnings
Kronos Bio (NASDAQ:KRON) reported its Q4 earnings results on Thursday, February 24, 2022 at 04:00 PM. Here's what investors need to know about the announcement.... 
Via Benzinga
Why Cutera Shares Are Trading Lower By 23%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers CinCor Pharma, Inc. (NASDAQ: CINC) shares jumped 137% to $27.93 after AstraZeneca announced it will acquire the company for $26 per share in cash. 
Via Benzinga
Kronos Bio Announces Discovery Collaboration with Genentech to Advance Novel Therapies Against Transcriptional Targets in Oncology
From Kronos Bio, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Friday
  OnFriday, 143 stocks hit new 52-week lows. 
Via Benzinga
Kronos Bio Presents Preclinical Data Supporting Anti-Leukemic Activity of Lanraplenib in Combination with Multiple Targeted Agents in Acute Myeloid Leukemia (AML) Preclinical Models at American Society of Hematology Meeting
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Selection of Recommended Phase 2 Dose for its Oral CDK9 Inhibitor, KB-0742, After Reaching Target Engagement Goal with Acceptable Safety Profile in Ongoing Phase 1/2 Clinical Trial
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Participation in Upcoming Investor Conferences
From Kronos Bio, Inc.
Via GlobeNewswire
Stocks That Hit 52-Week Lows On Wednesday
  During Wednesday's session, 107 stocks hit new 52-week lows. 
Via Benzinga
Stocks That Hit 52-Week Lows On Monday
  On Monday, 79 companies reached new 52-week lows. 
Via Benzinga
Palo Alto To Surge Around 38%? Plus This Analyst Predicts $65 For Helmerich & Payne
Barclays raised the price target on Palo Alto Networks, Inc. (NASDAQ: PANW) from $200 to $215. Barclays analyst Saket Kalia maintained an Overweight rating on the stock. Palo Alto Networks shares fell... 
Via Benzinga
Kronos Bio Reports Recent Business Progress and Third-Quarter 2022 Financial Results
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio Announces Prioritization of Clinical Portfolio to Focus on Lanraplenib and KB-0742
From Kronos Bio, Inc.
Via GlobeNewswire
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Pediatric Cancer Models in Poster Presentation at EORTC-NCI-AACR 2022
Company Plans to Provide Update and Recommended Phase 2 Dose from Ongoing KB-0742 Phase 1/2 Clinical Trial in Q4 2022 
From Kronos Bio, Inc.
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2022
Upgrades For Iris Energy Ltd (NASDAQ:IREN), Compass Point upgraded the previous rating of Neutral to Buy. The current stock performance of Iris Energy shows a 52-week-high of $17.97 and a 52-week-low... 
Via Benzinga
Recap Of Monday's Biotech Catalysts - End Of the Day Summary
Via Benzinga
Kronos Bio Shares Fall After Initial-Stage Blood Cancer Study Takes-off
Kronos Bio (NASDAQ: KRON) has initiated patient dosing in a Phase 1b/2 clinical trial of lanraplenib in combination with gilteritinib in patients with relapsed/refractory FLT3-mutated acute myeloid... 
Via Benzinga
The Week In Charts: The Trading Secret That's Really Not A Secret
Discussing the secret that's not, really; also recent winners, dealing with open profit drawdowns and more. 
Via Talk Markets
12 Health Care Stocks Moving In Thursday's Intraday Session
  
Via Benzinga
7 Nasdaq Stocks to Buy on the Dip
If you want to maximize your return potential and can handle some heat, here are compelling Nasdaq stocks to buy on the dip. 
Via InvestorPlace
38 Stocks Moving In Friday's Mid-Day Session
Gainers Leju Holdings Limited (NYSE: LEJU) surged 27.8% to $4.0413. 
Via Benzinga
66 Biggest Movers From Friday
Gainers GeoVax Labs, Inc. (NASDAQ: GOVX) shares surged 90.2% to settle at $1.39 on Friday. GeoVax Labs, last month, said its Q1 sales results were lower year over year. 
Via Benzinga
20 Stocks Moving in Friday's Pre-Market Session
Gainers Exicure, Inc. (NASDAQ: XCUR) shares rose 28.1% to $0.1550 in pre-market trading. Exicure said in Form4 filing a director bought 1,472,126 shares at average price of $0.19 per share. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
On Thursday, 236 companies hit new 52-week lows. 
Via Benzinga
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS